Are smart delivery systems the solution to overcome the lack of selectivity of current metallodrugs in cancer therapy?
Emerging molecular receptors for the specific-target delivery of ruthenium and gold complexes into cancer cells
Novel “ruthenium cyclopentadienyl”–peptide conjugate complexes against human FGFR(+) breast cancer
Selected as HOT TOPIC
New copper(i) complexes selective for prostate cancer cells
In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model
Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds
New water-soluble ruthenium(II) cytotoxic complex: Biological activity and cellular distribution